Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CS20AT04 in Lupus Nephritis
NCT03174587Phase 1Completed
- Sponsor
- Corestemchemon
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS20AT04 in lupus nephritis (LN), sponsored by Corestemchemon. Primary endpoint: Safety assessment(evaluation) at 28 days. Started May 2017; status: completed.
02
Drugs
CS20AT04
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03174587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174587.